Trial reportPLoS medicine2005
A malaria vaccine that elicits in humans antibodies able to kill Plasmodium falciparum.
Trial report in PLoS medicine, 2005. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 69 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
69 citing papers in PubMed, 1 synthesis or guideline pooled it, 152 citations in OpenAlex.
- Vaccines for preventing malaria (blood-stage).The Cochrane database of systematic reviews · 2006Pooled it
- Safety and immunogenicity of a recombinant nonglycosylated erythrocyte binding antigen 175 Region II malaria vaccine in healthy adults living in an area where malaria is not endemic.Clinical and vaccine immunology : CVI · 2010Trial
- Safety and immunogenicity of the malaria vaccine candidate MSP3 long synthetic peptide in 12-24 months-old Burkinabe children.PloS one · 2009Trial
- Satisfactory safety and immunogenicity of MSP3 malaria vaccine candidate in Tanzanian children aged 12-24 months.Malaria journal · 2009Trial
- Phase 1/2a study of the malaria vaccine candidate apical membrane antigen-1 (AMA-1) administered in adjuvant system AS01B or AS02A.PloS one · 2009Trial
- Phase I malaria vaccine trial with a long synthetic peptide derived from the merozoite surface protein 3 antigen.Infection and immunity · 2005Trial
- How to Accelerate Early Stage of Malaria Vaccine Development by Optimizing Functional Assays.Vaccines · 2024Review
- The Need for Novel Asexual Blood-Stage Malaria Vaccine Candidates forBiomolecules · 2024Review
- B-Cell Epitope Mapping of theVaccines · 2023Article
- Immunogenicity Analysis of the RecombinantPathogens (Basel, Switzerland) · 2022Article
- Plasmodium falciparum merozoite surface protein 3 as a vaccine candidate: a brief review.Revista do Instituto de Medicina Tropical de Sao Paulo · 2022Review
- Osteopontin and malaria: no direct effect on parasite growth, but correlation with P. falciparum-specific B cells and BAFF in a malaria endemic area.BMC microbiology · 2021Article
- A newly characterized malaria antigen on erythrocyte and merozoite surfaces induces parasite inhibitory antibodies.The Journal of experimental medicine · 2021Article
- Low genetic diversity and strong immunogenicity within the apical membrane antigen-1 of plasmodium ovale spp. imported from africa to china.Acta tropica · 2020Article
- Genetic polymorphism of merozoite surface protein-3 in Myanmar Plasmodium falciparum field isolates.Malaria journal · 2020Article
- AttenuatedFrontiers in immunology · 2020Article
- High-level artemisinin-resistance with quinine co-resistance emerges in P. falciparum malaria under in vivo artesunate pressure.BMC medicine · 2018Article
- Correlation of APRIL with production of inflammatory cytokines during acute malaria in the Brazilian Amazon.Immunity, inflammation and disease · 2018Article
- Article
- Profiling invasive Plasmodium falciparum merozoites using an integrated omics approach.Scientific reports · 2017Article
9 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 3 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundPlasmodium falciparum merozoite surface protein 3 is a malaria vaccine candidate that was identified, characterised, and developed based on a unique immuno-clinical approach. The vaccine construct was derived from regions fully conserved among various strains and containing B cell epitopes targeted by human antibodies (from malaria-immune adults) that are able to mediate a monocyte-dependent parasite killing effect. The corresponding long synthetic peptide was administered to 36 volunteers, with either alum or Montanide ISA720 as adjuvant. METHODS AND
findingsBoth formulations induced cellular and humoral immune responses. With alum, the responses lasted up to 12 mo. The vaccine-induced antibodies were predominantly of cytophilic classes, i.e., able to cooperate with effector cells. In vitro, the antibodies induced an inhibition of the P. falciparum erythrocytic growth in a monocyte-dependent manner, which was in most instances as high as or greater than that induced by natural antibodies from immune African adults. In vivo transfer of the volunteers' sera into P. falciparum-infected humanized SCID mice profoundly reduced or abrogated parasitaemia. These inhibitory effects were related to the antibody reactivity with the parasite native protein, which was seen in 60% of the volunteers, and remained in samples taken 12 mo postimmunisation.
conclusionThis is the first malaria vaccine clinical trial to clearly demonstrate antiparasitic activity by vaccine-induced antibodies by both in vitro and in vivo methods. The results, showing the induction of long-lasting antibodies directed to a fully conserved polypeptide, also challenge current concepts about malaria vaccines, such as unavoidable polymorphism, low antigenicity, and poor induction of immune memory.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.